Metastatic prostate cancer. Update: position paper for the use of chemotherapy
Ohlmann CH, Goebell P, Grimm MO, Klier J, Koenig F, Machtens S, Schostak M, Schrader AJ, Albers P (2017)
Publication Type: Journal article
Publication year: 2017
Journal
Book Volume: 56
Pages Range: 1597-1602
Journal Issue: 12
DOI: 10.1007/s00120-017-0459-4
Abstract
Taxen-based chemotherapy has been established as an effective treatment option in castration-resistant metastatic prostate cancer (mCRPC). Randomized phase III studies, however, have shown that even in the hormone-na < ve metastatic state, the early use of chemotherapy in addition to the classical androgen deprivation therapy (ADT) approach leads to a significant increase in median overall survival. This position paper aims to provide current data and orientation in the evidence-based treatment of mPC patients in daily clinical practice. A German group of clinical experts analyzed the current data and developed criteria for the treatment of mPC patients in daily clinical practice. In the current treatment of hormone-na < ve mPC, a beneficial effect of chemotherapy in addition to ADT has become evident. Provided patients are in an appropriate condition, those with a high metastatic load should receive chemotherapy in addition to ADT. Especially in high-risk mCRPC patients (PSA > 114 ng/ml, visceral metastasis, ADT response < 12 months, tumor-associated complaints), first-line chemotherapy is indicated. After docetaxel failure, continuous treatment with cabazitaxel shows superior overall survival compared to sustained antihormonal therapy. Chemotherapy is firmly established in treating patients with mCRPC. Long-term, it will be important to identify molecular predictors. The authors suggest the early use of chemotherapy in hormone-na < ve mPC, but note that the approval in this indication is currently nonexistent. After disease progression, patients should be treated analogous to mCRPC.
Authors with CRIS profile
Involved external institutions
Aturo - Fachärzte für Urologie und Andrologie
Germany (DE)
Universität des Saarlandes (UdS)
Germany (DE)
Marien-Krankenhaus Bergisch Gladbach
Germany (DE)
Universitätsklinikum Jena
Germany (DE)
Universitätsklinikum Münster
Germany (DE)
Universitätsklinikum Düsseldorf
Germany (DE)
Universitätsklinikum Magdeburg A.ö.R.
Germany (DE)
Germany (DE)
Universität des Saarlandes (UdS)
Germany (DE)
Marien-Krankenhaus Bergisch Gladbach
Germany (DE)
Universitätsklinikum Jena
Germany (DE)
Universitätsklinikum Münster
Germany (DE)
Universitätsklinikum Düsseldorf
Germany (DE)
Universitätsklinikum Magdeburg A.ö.R.
Germany (DE)
How to cite
APA:
Ohlmann, C.-H., Goebell, P., Grimm, M.-O., Klier, J., Koenig, F., Machtens, S.,... Albers, P. (2017). Metastatic prostate cancer. Update: position paper for the use of chemotherapy. Urologe, 56(12), 1597-1602. https://doi.org/10.1007/s00120-017-0459-4
MLA:
Ohlmann, C. -H., et al. "Metastatic prostate cancer. Update: position paper for the use of chemotherapy." Urologe 56.12 (2017): 1597-1602.
BibTeX: Download